Company research
Syra Health Corp
CIK 1922335Updated Sep 27, 2026
SecuritySYRA · OTC · equity
SYRA price & chart
Loading TradingView…
OTC:SYRA on TradingView ↗About the company
We are a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. We leverage deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. We provide comprehensive end-to-end solutions in behavioral and mental health, population health, digital health, health education and healthcare workforce. Our offerings are centered on prevention, improved access, and affordable care. Our goal is to supply our solutions to payers, providers, life sciences organizations, academic institutions, and the government.
In the news
Syra Health To Announce Third Quarter 2025 Financial Results News provided by Syra Health Nov 05, 2025, 08:55 ET Share this article Share to X Share this article Share to X CARMEL, Ind. , Nov. 5, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA ), ("Syra Health" or the "Company"), a healthcare so ↗
Recent filings
S-1 filing
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,772,917Source | 3,679,332Source | 4,923,283Source | 2,319,642Source |
| Property, Plant and Equipment, NetUSD | 6,986Source | 27,347Source | 78,974Source | 112,493Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,614,733Source | 2,395,405Source | 3,280,075Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 918,374Source | — | — | — |
| Assets, CurrentUSD | 2,738,530Source | 3,352,795Source | 4,781,110Source | 1,426,743Source |
| Prepaid Expense and Other Assets, CurrentUSD | 205,423Source | 276,563Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 27,401Source | 299,190Source | 63,199Source | 184,288Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 674,739Source | 800,761Source | 910,072Source | 1,609,544Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 11,806,765Source | 11,692,952Source | 9,071,745Source | 2,832,308Source |
| Retained Earnings (Accumulated Deficit)USD | -9,720,526Source | -8,824,193Source | -5,064,955Source | -2,126,612Source |
| Stockholders' Equity Attributable to ParentUSD | 2,098,178Source | 2,878,571Source | 4,013,211Source | 710,098Source |
| Liabilities and EquityUSD | 2,772,917Source | 3,679,332Source | 4,923,283Source | 2,319,642Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 674,739Source | 613,549Source | 910,072Source | 1,546,345Source |
| Operating Lease, Liability, CurrentUSD | 27,401Source | 111,978Source | 63,199Source | 121,089Source |
| Accounts Payable, CurrentUSD | — | 101,690Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | 187,212Source | — | 63,199Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 194,821Source | 230,383Source | 198,978Source | 239,117Source |
| Deferred Revenue, CurrentUSD | 16,611Source | 16,611Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 98,554Source | 59,803Source | 32,831Source | 2,910Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 237,547Source | -379,807Source | 59,547Source | 940,470Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -447,746Source | -2,932,033Source | -2,759,068Source | -2,244,065Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -107Source | -11,111Source | -15,251Source | -121,260Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 107Source | 11,111Source | 15,251Source | 121,260Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -332,819Source | 2,058,474Source | 6,051,050Source | 2,268,657Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -780,672Source | -884,670Source | 3,276,731Source | -96,668Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,614,733Source | 2,395,405Source | 3,280,075Source | 3,344Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 13,270Source | 15,600Source | 36,226Source | 11,651Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 21,041Source | — |
| DepreciationUSD | 20,468Source | 62,738Source | 48,771Source | 14,849Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| InterestExpenseNonoperatingUSD | 13,270Source | 15,600Source | — | — |
| Investment Income, InterestUSD | 21,261Source | 21,247Source | 2,942Source | 63Source |
| Net Income (Loss) Attributable to ParentUSD | -896,333Source | -3,759,238Source | -2,938,343Source | -2,118,165Source |
| Nonoperating Income (Expense)USD | 7,991Source | 5,647Source | -50,744Source | -28,470Source |
| Operating ExpensesUSD | 3,392,086Source | 5,417,848Source | 4,299,499Source | 3,151,477Source |
| Operating Lease, ExpenseUSD | 111,990Source | 299,190Source | 128,527Source | 175,555Source |
| Proceeds from Issuance of Common StockUSD | 14,800Source | 2,469,150Source | 5,332,283Source | 2,322,500Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 7,225,973Source | 7,982,082Source | 5,515,144Source | 5,617,706Source |
| Cost of RevenueUSD | 4,738,211Source | 6,329,119Source | 4,103,244Source | 4,555,924Source |
| Selling, General and Administrative ExpenseUSD | 1,065,376Source | 1,445,170Source | 1,131,922Source | 575,755Source |
| Operating Income (Loss)USD | -904,324Source | -3,764,885Source | -2,887,599Source | -2,089,695Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -896,333Source | -3,759,238Source | -2,938,343Source | -2,118,165Source |
| Earnings Per Share, BasicUSD per share | -0.08Source | -0.5Source | -0.6Source | -0.7Source |
| Earnings Per Share, DilutedUSD per share | -0.08Source | -0.5Source | -0.6Source | -0.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 11,852,347Source | 7,551,576Source | 4,877,861Source | 3,041,085Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 11,852,347Source | 7,551,576Source | 4,877,861Source | 3,041,085Source |
| Interest Expense (non-operating)USD | 13,270Source | 15,600Source | — | — |
| Additional Financial Items | ||||
| Gross ProfitUSD | 2,487,762Source | 1,652,963Source | 1,411,900Source | 1,061,782Source |
| Interest ExpenseUSD | — | 15,600Source | 53,686Source | 28,533Source |
| Investment Income, InterestUSD | 21,261Source | 21,247Source | 2,942Source | 63Source |
| Nonoperating Income (Expense)USD | 7,991Source | 5,647Source | -50,744Source | -28,470Source |
| Operating ExpensesUSD | 3,392,086Source | 5,417,848Source | 4,299,499Source | 3,151,477Source |
| Operating Lease, ExpenseUSD | 111,990Source | 299,190Source | 128,527Source | 175,555Source |
| Other ExpensesUSD | 13,988Source | — | — | — |
| Research and Development ExpenseUSD | 67,840Source | 585,146Source | 240,048Source | — |
Offerings
Registration 333-298924
Filing attachments
ex107.htm · S-1 · 2026-09-14
Calculation of Filing Fee Tables S-1 Syra Health Corp ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offer…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter Gross margin increased to 44.5% in Q2 2026, up from 38.7% in Q2 2025. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Syra Health sustained profitability in Q2 2026, following the Company’s first profitable quarter in Q1 2026, delivering net income of…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Syra Health Delivers its First Profitable Quarter in Q1 2026, Expands Margins and Strengthens Financial Position Syra Health delivered its first-ever profitable quarter in Q1 2026, with net income of approximately $241,000, representing a substantial 151% increase over the year-ago period Q1 2026 EPS grew to $0.02 per share versus ($0.04) in Q1 2025 Gross Margin rose to 42.7%, up 11 percentage points year-over-year Total revenu…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026 FY2025 EPS improved to ($0.08) compared to ($0.50) in FY2024 YoY net loss reduced 76% to ($896K) from ($3.8M) in FY2024 Population health revenue grew 157% to $5.3 million versus $2.1 million in FY2024 Operating expenses declined 37% to $3.4 million compared to $5.4 million in FY2024 Carmel, …
Read attachment ↗ex99-1.htm · 8-K · 2025-12-18
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact Carmel, Ind., December 18, 2025 / PRNewswire - Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), a healthcare solutions company dedicated to powering better heal…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Syra Health Announces Third Quarter Financial Results: Margins, Profitability Metrics Improve Q3 2025 Revenue of $1.7 Million Revenue driven by 96% year-over-year growth in the Population Health segment Gross margin improved 300 basis points to 33% in Q3 2025 from 30% in Q3 2024 Net loss decreased 46% year-over-year Earnings per share improved to ($0.02) for Q3 2025 compared to ($0.6) for Q3 2024 Carmel, Ind., November 12, 2025…
Read attachment ↗